pumosetrag
Small moleculeexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started Sep 1, 2005 (NCT00215566)
Timeline
2000s
- Jan 1, 2005
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
HTR3A agonist
- Serotonin 3 (5-HT3) receptorPARTIAL AGONIST
Serotonin 3 (5-HT3) receptor partial agonist
Chemistry & pharmacology
Loading structure…
SMILES
O=C(N[C@H]1CN2CCC1CC2)c1c[nH]c2ccsc2c1=O- Mol. weight
- 303.39 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL1643880 ↗
Also known as
- ddp733
- ddp733
- ddp733
- ddp733
- pumosetrag
- pumosetrag
- pumosetrag
- pumosetrag
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01161602 | Phase 2 | Jul 12, 2010 | Edusa Pharmaceuticals, Inc. |
| NCT00547469 | Phase 2/Phase 3 (Phase 3) | Oct 1, 2007 | Dynogen Pharmaceuticals |
| NCT00215566 | Phase 2 | Sep 1, 2005 | Dynogen Pharmaceuticals, University of Paris |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Dynogen Pharmaceuticals | For profit | 2 | 2 | 2 | 2005 |
| Edusa Pharmaceuticals, Inc. | For profit | 1 | 1 | 1 | 2010 |
| University of Paris | Academic/Hospital | 1 | 0 | 1 | 2005 |
3 organizations
Page 1 / 1